澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

RADIOPHARM THERANOSTICS LTD

0.004

-0.001-20.00%

成交量：2.27万

成交额：107

市值：1,884.35万

市盈率：-0.22

高：0.005

开：0.005

低：0.004

收：0.005

52周最高：0.037

52周最低：0.004

股本：47.11亿

流通股本：33.43亿

量比：0.01

换手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-0.019

每股收益(LYR):-0.019

净资产收益率：-174.71%

总资产收益率：-45.15%

市净率：0.76

市盈率(LYR):-0.22

数据加载中...

总览公司新闻资讯公告

Radiopharm Theranostics Ltd 披露：收到澳交所通知，涉嫌违反上市规则10.11

Radiopharm Theranostics：所有可评估胰腺癌患者均观察到显著肿瘤摄取

Radiopharm Theranostics：Rad301受试者安全性良好，生物分布表现积极

Radiopharm Theranostics公布Rad301在胰腺导管腺癌患者中的I期影像试验积极数据

Radiopharm Theranostics年度初步亏损扩大50.3% 截至2026年6月30日财年亏损达5515万澳元

Radiopharm Theranostics启动Betabart（Rv-01）治疗B7-H3阳性实体瘤1/2a期临床试验第二队列首例患者给药

Radiopharm Theranostics公司Rad202研究获临床概念验证安全性与生物分布数据积极

Radiopharm Theranostics获数据安全监查委员会积极推荐，177Lu-Rad202一期HEAT临床试验推进至第4队列

Radiopharm Theranostics：推进RAD202一期临床试验至180Mci剂量，针对HER2阳性晚期实体瘤

Radiopharm Theranostics定于2026年10月1日召开FDA二期结束会议，为Rad101三期试验铺路

Radiopharm Theranostics同步推进410万美元注册直接发行与最高1270万澳元（约合890万美元）澳大利亚配售及购股计划

Radiopharm Theranostics在Rad204针对免疫疗法后晚期实体瘤患者的1期试验中获得确认的持久部分缓解

Radiopharm Theranostics旗下Rad101在六个月随访中展现86%初步灵敏度；特异性数据预计2026年第四季度公布

Radiopharm Theranostics公布脑转移诊断药物Rad 101二期B阶段试验积极结果

Radiopharm Theranostics完成美国Rad 101诊断脑转移瘤IIb期影像学试验患者入组

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/RAD.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.004,"timestamp":1791857814745,"preClose":0.005,"halted":0,"volume":22672,"delay":0,"changeRate":-0.2,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4710883000,"eps":-0.01853,"marketStatus":"交易中","change":-0.001,"latestTime":"10-13 13:17:43 AEDT","open":0.005,"high":0.005,"low":0.004,"amount":107,"amplitude":0.2,"askPrice":0.005,"askSize":4727571,"bidPrice":0.004,"bidSize":8670773,"shortable":3,"etf":0,"ttmEps":-0.01853,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791867600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.005,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":0.009322,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.005,"auctionPrice":0.005,"auctionVolume":3704,"auction":3,"marketStatus":"盘后竞价","timestamp":1791781783455}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-45.15%","roe":"-174.71%","lyrEps":-0.01853,"volumeRatio":0.009322,"shares":4710883000,"dividePrice":0,"high":0.005,"amplitude":0.2,"preClose":0.005,"low":0.004,"week52Low":0.004,"pbRate":"0.76","psRate":"1.46","week52High":0.037,"institutionHeld":0,"latestPrice":0.004,"committee":0.294305,"eps":-0.01853,"divideRate":0,"volume":22672,"delay":0,"ttmEps":-0.01853,"open":0.005,"prevYearClose":0.025,"prevWeekClose":0.005,"prevMonthClose":0.006,"prevQuarterClose":0.006,"fiveDayClose":0.005,"twentyDayClose":0.008,"sixtyDayClose":0.019,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1135157540","title":"Radiopharm Theranostics Ltd 披露：收到澳交所通知，涉嫌违反上市规则10.11","url":"https://stock-news.laohu8.com/highlight/detail?id=1135157540","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135157540?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 09:33","pubTimestamp":1791768788,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd 对外宣布，该公司已接到澳大利亚证券交易所（ASX）的通知，指出其存在违反上市规则10.11条的情形。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106926898","title":"Radiopharm Theranostics：所有可评估胰腺癌患者均观察到显著肿瘤摄取","url":"https://stock-news.laohu8.com/highlight/detail?id=1106926898","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106926898?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 19:11","pubTimestamp":1788952276,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics传来重磅消息——在其相关研究中，所有可评估的胰腺癌患者均表现出了显著的肿瘤摄取现象。这一发现无疑为胰腺癌诊疗领域投下了一枚震撼弹。据悉，该结果可能为后续更精准的靶向治疗与成像策略奠定关键基础，其临床意义不容小觑。业界普遍关注，这一积极信号能否顺利转化为切实可行的治疗方案，从而惠及广大患者群体。市场对此消息的初步反应亦颇为敏感，投资者正密切观望后续的详细数据披露与监管审批动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124219327","title":"Radiopharm Theranostics：Rad301受试者安全性良好，生物分布表现积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1124219327","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124219327?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 19:11","pubTimestamp":1788952273,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司宣布，其候选药物Rad301在临床试验中展现出令人鼓舞的结果。所有接受该药物剂量给药的研究对象均表现出良好的安全性，同时生物分布数据也呈现有利态势。这一积极进展为公司研发管线注入了新的信心，Rad301作为潜在治疗方案的可行性与耐受性获得了初步验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141615521","title":"Radiopharm Theranostics公布Rad301在胰腺导管腺癌患者中的I期影像试验积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1141615521","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141615521?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 19:02","pubTimestamp":1788951758,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics今日宣布，其候选药物Rad301在针对胰腺导管腺癌患者的I期影像学临床试验中取得了令人振奋的积极结果。这一进展为该公司在肿瘤精准诊断领域的布局注入了新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172086213","title":"Radiopharm Theranostics年度初步亏损扩大50.3% 截至2026年6月30日财年亏损达5515万澳元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172086213","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172086213?lang=zh_cn&edition=fundamental","pubTime":"2026-08-28 14:10","pubTimestamp":1787897411,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics（澳大利亚证券交易所代码：RAD.AU）披露了截至2026年6月30日的年度初步财务业绩，数据显示该公司年度应占亏损同比扩大50.3%，达到5515万澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191690899","title":"Radiopharm Theranostics启动Betabart（Rv-01）治疗B7-H3阳性实体瘤1/2a期临床试验第二队列首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1191690899","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191690899?lang=zh_cn&edition=fundamental","pubTime":"2026-08-26 19:03","pubTimestamp":1787742188,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司宣布，其针对B7-H3阳性实体瘤的候选药物Betabart在1/2a期临床试验中，已顺利完成第二队列首例患者的给药。Betabart作为一种靶向B7-H3的放射性治疗药物，其设计理念在于将放射性同位素精准递送至肿瘤细胞表面高表达的B7-H3抗原，从而实现针对性的杀伤效果，同时尽可能减少对周围正常组织的损伤。B7-H3在多种实体瘤中广泛表达，与肿瘤的发生发展及不良预后密切相关，因此成为癌症治疗领域备受关注的热门靶点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119579747","title":"Radiopharm Theranostics公司Rad202研究获临床概念验证 安全性与生物分布数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1119579747","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119579747?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 19:02","pubTimestamp":1787223725,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司公布了一项关于其候选药物Rad202的最新研究成果。该研究结果标志着该药物在临床试验中取得了重要的概念验证，其安全性和生物分布方面的表现均呈现积极态势。具体而言，这项研究为Rad202的后续开发奠定了坚实基础。它不仅验证了Rad202的科学原理，也进一步增强了市场对公司研发管线和整体技术平台的信心。公司认为，这一进展将有助于推动该候选药物进入下一阶段的临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171695853","title":"Radiopharm Theranostics获数据安全监查委员会积极推荐，177Lu-Rad202一期HEAT临床试验推进至第4队列","url":"https://stock-news.laohu8.com/highlight/detail?id=1171695853","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171695853?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 19:01","pubTimestamp":1787223679,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics宣布，其数据安全监查委员会已给出积极推荐意见，同意177Lu-Rad202一期HEAT临床试验向前推进至第4队列。这一关键进展标志着该研究项目迈入新的阶段，为后续研发铺平了道路。委员会基于现有数据的安全性和可行性评估，作出了支持继续推进的决定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192885524","title":"Radiopharm Theranostics：推进RAD202一期临床试验至180Mci剂量，针对HER2阳性晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1192885524","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192885524?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 19:01","pubTimestamp":1787223676,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics宣布，其RAD202一期临床试验已推进至180Mci剂量水平，该试验针对HER2阳性晚期实体瘤患者。这一进展标志着公司在放射性药物开发领域的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107926876","title":"Radiopharm Theranostics定于2026年10月1日召开FDA二期结束会议，为Rad101三期试验铺路","url":"https://stock-news.laohu8.com/highlight/detail?id=1107926876","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107926876?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 19:31","pubTimestamp":1786966268,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司已正式敲定，将于2026年10月1日与美国食品药品监督管理局（FDA）举行一场关键的二期结束会议。此次会议的核心议题，是围绕其备受瞩目的Rad101药物所即将启动的三期临床试验展开深入磋商与交流。这一重要日程的安排，标志着该公司在推进其放射性药物管线进程中，又迈出了具有战略意义的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183705268","title":"Radiopharm Theranostics同步推进410万美元注册直接发行与最高1270万澳元（约合890万美元）澳大利亚配售及购股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1183705268","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183705268?lang=zh_cn&edition=fundamental","pubTime":"2026-07-24 19:16","pubTimestamp":1784891770,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics宣布了一项重大融资举措：同步启动410万美元的注册直接发行，并计划在澳大利亚进行最高1270万澳元（约合890万美元）的配售及购股计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153196759","title":"Radiopharm Theranostics在Rad204针对免疫疗法后晚期实体瘤患者的1期试验中获得确认的持久部分缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1153196759","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153196759?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 19:06","pubTimestamp":1784718381,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics在其正在进行的Rad204药物1期临床试验中取得积极进展。该试验针对既往接受过免疫疗法但病情仍出现进展的晚期实体瘤患者，目前已观察到获得确认的持久性部分缓解的病例。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194417652","title":"Radiopharm Theranostics旗下Rad101在六个月随访中展现86%初步灵敏度；特异性数据预计2026年第四季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1194417652","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194417652?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 19:03","pubTimestamp":1784718195,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd (ASX: RAD) 公布了其放射性药物候选产品Rad101的最新临床数据，该产品在为期六个月的随访中显示出高达86%的初步灵敏度。此项积极结果标志着该疗法在诊断应用领域取得了重要进展。\n公司预计，关于Rad101的特异性关键数据将于2026年第四季度对外公布。特异性数据的出炉，将为进一步评估该药物的整体诊断效能提供至关重要的补充信息，从而为未来的临床开发与潜在应用奠定更坚实的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127955453","title":"Radiopharm Theranostics公布脑转移诊断药物Rad 101二期B阶段试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1127955453","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127955453?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 19:01","pubTimestamp":1784718075,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics宣布其用于诊断脑转移的候选药物Rad 101，在二期B阶段临床试验中取得了积极成果。该试验结果标志着公司在精准肿瘤诊断领域取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123883160","title":"Radiopharm Theranostics完成美国Rad 101诊断脑转移瘤IIb期影像学试验患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1123883160","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123883160?lang=zh_cn&edition=fundamental","pubTime":"2026-04-16 19:01","pubTimestamp":1776337312,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd (RAD.AU) 宣布已顺利完成其在美国开展的Rad 101诊断脑转移瘤IIb期影像学试验的患者招募工作。该试验旨在评估Rad 101在脑转移瘤诊断中的应用效果，标志着公司在核医学诊疗领域取得重要阶段性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}